Sammanfattning
Transcatheter aortic valve implantation (TAVI) is a new less invasive treatment for aortic stenosis and has been performed in Sweden since 2008. Significant aortic stenosis is common in the elderly population and has a high mortality, which can be lowered by aortic valve replacement only. However, a significant number of patients are not good candidates for surgery due to comorbidities or high age. It has been shown that TAVI significantly reduces mortality and symptoms in patients who cannot have surgery, compared to medical treatment only. In high risk but operable patients, mortality is similar after TAVI and surgical aortic valve replacement. Ongoing studies comparing surgical and transcatheter aortic valve implantation will further define the role of percutaneous treatment in aortic stenosis.